US · Healthcare · Biotechnology
EPS came in at 0.43 against a street estimate of 0.12 — a beat of 258.3%.
Analysts rate Regenxbio Inc a buy (10 buy, 2 hold, 0 sell out of 12) with an average price target of $24.55.
| Fund | Stake |
|---|---|
| BlackRock Inc | 9.69% |
| Redmile Group, LLC | 6.62% |
| State Street Corp | 4.50% |
| JPMorgan Chase & Co | 3.35% |
| Vanguard Capital Management, LLC | 3.19% |
| Morgan Stanley - Brokerage Accounts | 2.96% |
| The Goldman Sachs Group Inc | 2.15% |
| AQR Capital Management LLC | 2.09% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Regenxbio Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.